Truist lowered the firm’s price target on AMN Healthcare (AMN) to $47 from $50 and keeps a Buy rating on the shares. The company reported mixed Q3 results and issued downside Q4 guidance as EBITDA margins fell 500bps, the analyst tells investors in a research note. Truist adds however that demographic shifts, increasingly complex regulatory requirements, and AMN’s high quality interpreters should enable market share gain opportunities for the language services division.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMN: